Cardiovascular outcome trials of diabetes drugs: lessons learned

被引：9
作者：
Taylor, Simeon I. [1 ]
Leslie, Bruce R. [2 ]
机构：
[1] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Seventh Doctor Consulting, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2018年 / 128卷 / 03期
关键词：
TYPE-2; EMPAGLIFLOZIN; LIRAGLUTIDE; EVENTS; DEATH;
D O I：
10.1172/JCI99820
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：893 / 896
页数：4
相关论文
共 29 条
  • [1] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
    不详
    [J]. DIABETES CARE, 2018, 41 : S73 - S85
  • [2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [3] Department of Health Education and Welfare, 2014, J Am Coll Dent, V81, P4
  • [4] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [5] FDA, 2008, END MET DRUG ADV C 3
  • [6] FDA, 2016, END MET DRUG ADV COM
  • [7] FDA, 2008, END MET DRUG ADV C 1
  • [8] FDA, 2008, END MET DRUGS ADV 2
  • [9] Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
    Gaziano, J. Michael
    Cincotta, Anthony H.
    Vinik, Aaron
    Blonde, Lawrence
    Bohannon, Nancy
    Scranton, Richard
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (05):
  • [10] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Buse, John B.
    Engel, Samuel S.
    Garg, Jyotsna
    Josse, Robert
    Kaufman, Keith D.
    Koglin, Joerg
    Korn, Scott
    Lachin, John M.
    McGuire, Darren K.
    Pencina, Michael J.
    Standl, Eberhard
    Stein, Peter P.
    Suryawanshi, Shailaja
    Van de Werf, Frans
    Peterson, Eric D.
    Holman, Rury R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) : 232 - 242
123